Lunai Bioworks Inc. Launches Innovative AI Platform to Enhance Drug Discovery and Security

Lunai Bioworks Inc., a leader in AI-driven drug discovery and biodefense, unveiled a groundbreaking transformer-based platform. This innovation embeds biological risk intelligence into large language model pipelines. By employing virtual chemical screening, the platform identifies potentially toxic compounds, accelerating therapeutic development.

As generative AI reshapes healthcare and biotech, safety is paramount. The platform integrates proprietary neurotoxicity intelligence into workflows, addressing concerns about AI's dual-use potential. This integration allows the safe advancement of new medicines while preventing the creation of hazardous compounds.

Chief Scientific Officer Dr. Gabe Musso highlights the platform's dual benefits in speeding up therapeutic discoveries and safeguarding against new chemical threats. Key advantages include a unique data advantage from extensive zebrafish-based assays and robust technology that sets a real-time safeguard within AI pipelines.